What Is 5-Amino-1MQ? The NNMT Inhibitor, Explained
The short answer
5-amino-1MQ is a synthetic small molecule, chemically a quinolinium salt, that blocks the activity of NNMT, an enzyme involved in cellular methylation and NAD+ metabolism. It is not a peptide, not a hormone analog, and not related to GLP-1 receptor agonists. Interest in it comes from mouse studies showing that inhibiting NNMT with this compound reduced weight gain and altered fat tissue metabolism in diet-induced obese mice (Neelakantan et al. 2018). That is a meaningfully different evidence base than a completed human trial, and readers marketed to as if this is a proven fat-loss agent are being given more certainty than the science supports.
What is NNMT, and why would inhibiting it matter?
Nicotinamide N-methyltransferase (NNMT) is an enzyme that transfers a methyl group from SAM (S-adenosylmethionine) to nicotinamide, producing N1-methylnicotinamide. This reaction sits at a metabolic crossroads: it consumes methyl donors that would otherwise be available for other cellular methylation reactions, and it affects nicotinamide availability for NAD+ salvage pathways (Neelakantan review, 2021).
NNMT expression is elevated in adipose tissue in obesity and appears responsive to glucose availability in adipocytes (Kannt lab, 2020). Higher NNMT activity has been associated with reduced cellular methylation capacity and altered energy metabolism in fat and liver tissue, which is the mechanistic basis for the hypothesis that blocking NNMT could shift energy balance toward fat oxidation (NNMT in obesity and type 2 diabetes, 2021; NNMT as a metabolic syndrome target, 2024).
This is a plausible mechanism, not a demonstrated human outcome. Enzyme biology and mouse phenotypes do not automatically translate to comparable effects, or comparable safety, in people.
Is 5-amino-1MQ a peptide?
No. This distinction matters because 5-amino-1MQ is frequently sold alongside actual peptides (BPC-157, ipamorelin, and similar) in the same online marketplaces, which blurs the regulatory and safety picture for buyers. 5-amino-1MQ is a small organic molecule with a defined chemical structure, developed and characterized as a selective NNMT inhibitor in enzyme assay and medicinal chemistry work (selective membrane-permeable NNMT inhibitors, 2018; novel tricyclic NNMT inhibitors, 2022). Peptides are chains of amino acids and are regulated, sourced, and metabolized differently. Lumping the two categories together, as much retail marketing does, obscures rather than clarifies what a buyer is actually taking. For the mechanistic detail on NNMT inhibition itself, see our NNMT inhibition mechanism page.
What does the animal evidence actually show?
The most cited data point is a 2018 study in which 5-amino-1MQ, given to diet-induced obese mice, reduced body weight gain and reversed some markers of high-fat-diet-induced obesity (Neelakantan et al. 2018). A separate small-molecule NNMT inhibitor program reported similar metabolic effects in obese mouse models (Scientific reports, 2018), and a related paper found that combining a reduced-calorie diet with NNMT inhibition changed gut microbiome composition in diet-induced obese mice (2022).
There is also pharmacokinetic work in rats establishing an LC-MS/MS assay and oral bioavailability data for 5-amino-1MQ, which is a necessary step toward any human dosing conversation but is itself only an animal PK study (2021). We cover what that bioavailability data does and does not support on the oral bioavailability page.
No study in this evidence base reports human weight, body composition, or safety outcomes for 5-amino-1MQ. That gap is the central fact a reader needs before treating any fat-loss claim as established.
What is not established
Claims that circulate in marketing copy, that 5-amino-1MQ produces reliable human fat loss, preserves lean muscle mass during a deficit, or is safe at any particular dose in people, are not supported by the sources above. Some separately studied NNMT-pathway molecules, like N1-methylnicotinamide, have limited human data in narrower contexts such as athletic supplementation (2022 review), but that is a different compound and does not transfer to 5-amino-1MQ's safety or efficacy. We detail the muscle-related claims specifically on the muscle research page and the weight-loss claims on the weight-loss evidence page.
Where does it stand with FDA?
5-amino-1MQ has no FDA-approved indication for any use. It is not currently listed on FDA's 503A bulk drug substances list used for compounding (FDA bulk substances framework), which means compounded versions sold through pharmacies are operating without that specific regulatory basis. This status can change, and readers should check current standing rather than rely on a static claim; our FDA status page and the FDA Peptide Status Tracker track this. As of this writing (September 2026), no approval or clearance exists for 5-amino-1MQ in any indication.
How does it compare to other options people consider?
Readers researching NNMT inhibitors for weight management are often also looking at GLP-1 receptor agonists (semaglutide, tirzepatide) or at berberine, an unrelated small molecule with its own separate evidence base. These are mechanistically distinct from 5-amino-1MQ and from each other, and none of the comparisons should be read as equivalence. See 5-amino-1MQ vs GLP-1 agents and 5-amino-1MQ vs berberine for what is and is not comparable across the human evidence each has.
A framework for reading any 5-amino-1MQ claim
Before accepting a marketing claim about this compound, ask where it sits on this ladder. Each rung requires a stronger form of evidence than the one below it, and current 5-amino-1MQ claims mostly sit on the bottom two rungs.
Evidence-tier check for 5-amino-1MQ claims
| Tier | What it would require | Does 5-amino-1MQ have it? |
|---|---|---|
| 1. Regulatory approval | FDA-approved label for a stated indication | No, none exists |
| 2. Clinical guideline | A professional body recommending use in humans | No |
| 3. Human trial evidence | Published randomized or controlled human study | Not found in current literature |
| 4. Animal/in vivo evidence | Rodent studies on weight, metabolism, PK | Yes, several diet-induced obesity mouse studies |
| 5. In vitro/enzyme evidence | Cell-based or biochemical assay data | Yes, extensive enzyme inhibitor characterization work |
If a seller's claim implies tier 1-3 support ("clinically proven," "FDA-recognized pathway," "safe for humans"), and the linked evidence only reaches tier 4 or 5, that is a red flag worth pausing on before purchase.
Safety, sourcing, and practical questions
Because no human trials exist, there is no established human dose, no characterized side-effect profile, and no data on drug interactions or contraindications for 5-amino-1MQ. Anyone considering it should treat unverified vendor dosing claims with skepticism; we cover the specific claims made about dosing on the dosing claims page and general safety signal gaps on the side effects and safety page. If someone has already used a compounded or research-grade product and experiences symptoms such as chest pain, difficulty breathing, severe abdominal pain, or signs of an allergic reaction, that is a reason for urgent medical evaluation, not a wait-and-see approach, given the absence of human safety data to reassure against serious reactions.
For readers weighing sourcing and cost against the current evidence gap, our how to get 5-amino-1MQ page, cost factors page, and evidence quality overview walk through what a buyer is actually paying for given the regulatory and clinical status described here.
The honest position is narrower than most marketing pages allow: 5-amino-1MQ is a real, well-characterized enzyme inhibitor with genuine mechanistic interest for NAD+ and methylation biology, backed by consistent preclinical findings in obese mice. It is not, at this point, a substance with human trial data behind its weight-loss reputation, and treating mouse metabolic data as if it predicts human fat-loss results overstates what the current literature supports.